Randomized Controlled Trial of RTS,S/AS02D and RTS,S/AS01E Malaria Candidate Vaccines Given According to Different Schedules in Ghanaian Children

Abstract

BackgroundThe target delivery channel of RTS,S candidate malaria vaccines in malaria-endemic countries in Africa is the World Health Organisation Expanded Program on Immunization. As an Adjuvant System, age de-escalation and schedule selection step, this study assessed 3 schedules of RTS,S/AS01E and RTS,S/AS02D in infants and young children 5–17 months of age in Ghana.MethodologyA Phase II, partially-blind randomized controlled study (blind to vaccine, not to schedule), of 19 months duration was conducted in two (2) centres in Ghana between August 2006 and May 2008. Subjects were allocated randomly (1∶1∶1∶1∶1∶1) to one of six study groups at each study site, each defining which vaccine should be given and by which schedule (0,1-, 0,1,2- or 0,1,7-months). For the 0,1,2-month schedule participants received RTS,S/AS01E or rabies vaccine at one center and RTS,S/AS01E or RTS,S/AS02D at the other. For the other schedules at both study sites, they received RTS,S/AS01E or RTS,S/AS02D. The primary outcome measure was the occurrence of serious adverse events until 10 months post dose 1.ResultsThe number of serious adverse events reported across groups was balanced. One child had a simple febrile convulsion, which evolved favourably without sequelae, considered to be related to RTS,S/AS01E vaccination. Low grade reactions occurred slightly more frequently in recipients of RTS,S/AS than rabies vaccines; grade 3 reactions were infrequent. Less local reactogenicity occurred with RTS,S/AS01E than RTS,S/AS02D. Both candidate vaccines were highly immunogenic for anti-circumsporozoite and anti-Hepatitis B Virus surface antigen antibodies. Recipients of RTS,S/AS01E compared to RTS,S/AS02D had higher peak anti-circumsporozoite antibody responses for all 3 schedules. Three dose schedules were more immunogenic than 2 dose schedules. Area under the curve analyses for anti-circumsporozoite antibodies were comparable between the 0,1,2- and 0,1,7-month RTS,S/AS01E schedules.ConclusionsBoth candidate malaria vaccines were well tolerated. Anti-circumsporozoite responses were greater with RTS,S/AS01E than RTS,S/AS02D and when 3 rather than 2 doses were given. This study supports the selection of RTS,S/AS01E and a 3 dose schedule for further development in children and infants.Trial RegistrationClinicalTrials.gov NCT00360230

Effects on Immunogenicity by Formulations of Emulsion-Based Adjuvants for Malaria Vaccines

“…In addition, modest pain reduction was noted at the lower adjuvant dose compared to the full dose. Finally, clinical trial results showed reduced reactogenicity in children receiving a malaria vaccine containing AS01 (a liposome adjuvant system containing MPL and QS21) compared to the same vaccine containing AS02 (an emulsion adjuvant system containing MPL and QS21) (26). Taken together, the MF59 and AS series clinical trials demonstrate that reduction or removal of oil content has the potential to reduce local reactogenicity, although this effect may depend on each vaccine's composition and its intended recipients.…”

Cryogenic transmission electron microscopy of recombinant tuberculosis vaccine antigen with anionic liposomes reveals formation of flattened liposomes

“…Fox et al compounds when combined with a recombinant malaria vaccine; 6 this vaccine is now in Phase III clinical trials in African children. We have developed an anionic liposomal formulation containing GLA (GLA-LS) and demonstrated protective immune responses in mice when combined with ID93, 7 although T helper type 1 immunogenicity markers were not induced to the same magnitude as with GLA-SE.…”

Protective Humoral Immunity Elicited by a Needle-Free Malaria Vaccine Comprised of a Chimeric Plasmodium falciparum Circumsporozoite Protein and a Toll-Like Receptor 5 Agonist, Flagellin

“…Immunogenicity of the RTS,S vaccine is adjuvant dependent, and a formulation in alum, the aluminum adjuvant present in most licensed vaccines, elicited suboptimal protection against sporozoite challenge (10,11). The current RTS,S adjuvant formulation was derived empirically and is comprised of a mixture of monophosphoryl lipid A (MPL) and QS21, a purified fraction of the detergent saponin, in an oil-in-water emulsion (AS02) or a liposome (AS01) formulation (12,13).…”